echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > "Journal of Hepatology" Pfizer's new crown vaccine latest side effects: or lead to hepatitis cirrhosis liver failure?

    "Journal of Hepatology" Pfizer's new crown vaccine latest side effects: or lead to hepatitis cirrhosis liver failure?

    • Last Update: 2022-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Pfizer just released the data of the second batch of vaccines, which once again caused heated discussions and discussions on the entire Internet


    The latest clinical research from Germany found:

    COVID-19 mRNA vaccine (BNT162b2) jointly developed by Pfizer and BioNTech may cause rare T cell-mediated autoimmune hepatitis! 

    Autoimmune hepatitis is a chronic progressive inflammatory disease of the liver mediated by an autoimmune response


    Severe cases can rapidly develop into liver cirrhosis and liver failure


    The above research was published in the April 21 issue of the international authoritative journal of liver disease "Journal of Hepatology"


     

     

    Clinical studies have reported bimodal flares of acute hepatitis following two doses of Pfizer's mRNA vaccine, with flares occurring after both doses


    The male patient in the study was 52 years old and had no medical history other than hypothyroidism


    The study found that male patients developed jaundice 10 days after the first injection of the mRNA vaccine, and liver function tests (LFT) showed acute mixed hepatocellular/cholestatic hepatitis


    On day 25 of vaccination, the patient was hospitalized


    Subsequently, 41 days after the first vaccination, the patient received a second dose of the BNT162b2 vaccine


    The patient was transferred to a tertiary care center for treatment 26 days after the second vaccination


    To find the cause of the patient's hepatitis, the researchers performed serology, polymerase chain reaction (PCR) testing on the patient to rule out hepatitis A, B, C or E, cytomegalovirus (CMV) and Epstein-Barr virus possibility of infection


    Autoimmune serology showed mild hyperglobulinemia, borderline positive for antinuclear antibody (ANA), antimitochondrial M2 antibody (AMA-M2), and antismooth muscle antibody, and negative for LKM antibody


     

     

    The researchers then performed a liver biopsy in the patient and found that the patient's hepatitis had moderate lymphoplasmacytic infiltration with foci of lobular necrosis and apoptosis


    The 52-year-old's symptoms were consistent with autoimmune hepatitis, the researchers said


    Through the study of various factors, the research team believes that vaccination with BNT162b2 may trigger immune-mediated hepatitis through cellular immune mechanisms


    These results suggest that T cells are the key pathogenic immune cell type in this vaccine-associated immune hepatitis, a new subtype of autoimmune hepatitis


     

    (Source: Internet, reference only)


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.